Pressure BioScience (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based instruments,
consumables and platform-technology solutions to the worldwide life sciences
and other industries, recently announced the opening of its new Ultra Shear
Technology(TM) (“UST”) Demonstration Laboratory (http://ibn.fm/veoMI). An article
discussing the company reads, “The main goal of the UST Demo Lab is to showcase
the ability of the company’s revolutionary UST Platform to process cannabidiol
(‘CBD’) oil into water-soluble nanoemulsions of superior quality. CBD
nanoemulsions are expected to be more stable and offer higher bioavailability
than the standard macro and microemulsions used in the vast majority of CBD
products today. . . . The second objective is to invite potential purchasers of
the company’s BaroShear nanoemulsification system to evaluate how their CBD and
other product formulations work with the company’s revolutionary UST platform.
The company expects to install and invoice the initial 12 BaroShear K45 systems
in the fourth quarter of 2020.”
To view the full article, visit http://ibn.fm/jEHQt
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale
of innovative, broadly enabling, pressure-based solutions for the worldwide
life-sciences industry. The company’s products are based on the unique
properties of both constant (i.e., static) and alternating (i.e.,
pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented,
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil and plant biology, forensics and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired, patented technology from BaroFold
Inc. (the “BaroFold” technology) to allow entry into the biopharma contract
services sector, and (2) the use of its recently patented, scalable,
high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i)
create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and
water) and (ii) prepare higher-quality, homogenized, extended shelf-life or
room-temperature, stable, low-acid liquid foods that cannot be effectively
preserved using existing nonthermal technologies. For more information, visit
the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
